Search

Search Constraints

You searched for: Author/Creator Rifkin, Robert M.

Search Results

2. Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis. Issue 19 (24th July 2020)

3. Connect MM Registry as a national reference for United States multiple myeloma patients. (7th November 2019)

4. Connect MM® – the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide. Issue 9 (1st September 2016)

5. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. (3rd March 2019)

6. Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study. Issue 10 (24th August 2022)

7. Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry. (5th August 2019)

8. Effect of initial treatment on health‐related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry. (29th October 2020)

9. Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies. Issue 10 (3rd September 2018)

10. Recognition of early mortality in multiple myeloma by a prediction matrix. Issue 9 (19th July 2017)